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Abstract
Background: The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in
experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement in
outcome of patients with osteosarcoma. Prognosis of osteosarcoma is still severe and only few patients survive
beyond five years. We performed a prospective immunohistochemistry analysis to correlate YY1 immunostaining
with metastatic development and survival in a selected homogeneous group of patients with osteosarcoma.
Methods: We studied 41 patients suffering from osteosarcoma (stage II-IVa). Multivariate analysis was performed
using Cox proportional hazard regression to evaluate the correlation between YY1 expression and both metastasis
development and mortality.
Results: YY1 protein is not usually present in normal bone; in contrast, a high number of patients (61%) showed a
high score of YY1 positive cells (51-100%) and 39% had a low score (10-50% positive cells). No statistical difference
was found in histology, anatomic sites, or response to chemotherapy between the two degrees of YY1 expression.
Cox regression analysis demonstrated that the highest score of YY1 expression was predictive of both low
metastasis-free survival (HR = 4.690, 95%CI = 1.079-20.396; p = 0.039) and poor overall survival (HR = 8.353, 95%CI
= 1.863-37.451 p = 0.006) regardless of the effects of covariates such as age, gender, histology and chemonecrosis.
Conclusion: Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis
and poor clinical outcome.
Background
Osteosarcoma is the most common primary malignant
bone tumor in adolescents and children [1]. It occurs
frequently in long bones and metastasizes preferentially
to the lung [1]. Despite recent advances in chemother-
apy, the 5-year event-free survival and overall survival
rates, closely linked to grade of osteosarcoma, are
around 50-60%. This is due to the development of resis-
tance to multiple types of chemotherapy and radiother-
apy [2-4]. Clinical stage of the disease and several
clinical biomarkers have been correlated with the
outcome [5-11]. Nonetheless, these prognostic factors
have limited utility in terms of predicting survival [12].
The ubiquitous, conserved, multifunctional polycomb
transcription factor Yin Yang 1 (YY1) plays a pivotal
role in biological processes [13-15]. YY1 regulates
embryonic blood formation and its downstream hox
genes, X chromosome inactivation, differentiation, and
cell cycle [13,14]. The majority of the data are consistent
with the hypothesis that YY1 overexpression and/or its
activation is associated with unchecked cellular prolif-
eration, resistance to apoptotic stimuli, tumorigenesis
and metastatic potential. We studied the role of YY1 in
osteosarcoma carcinogenesis and tumor progression.
YY1 is overexpressed in osteosarcoma cells and bioptic
specimens, and is correlated with a high degree of
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malignancy [16,17]. Moreover, YY1 silencing has been
shown to be sufficient to significantly reduce osteosar-
coma metastatic growth and neoangiogenesis in a nude
mice model [18-20]. To date, there is no evidence of
correlation between YY1 overexpression and clinical
outcome in osteosarcoma patients. Thus, we designed a
prospective study to analyze whether YY1 expression in
the primary tumor of osteosarcoma patients could pre-
dict metastasis-free and overall survival.
Methods
Patients
We enrolled 41 osteosarcoma patients (stage II-IVa
UICC/AJCC classification) from the Department of
Pathology of the Istituto Ortopedico Rizzoli (Bologna,
Italy) and from the Division of Surgical Pathology, Isti-
tuto Nationale Tumori, Fondazione G. Pascale (Naples,
Italy), under their Local Ethical Committee approval. We
used the bioptic samples of primary tumor before any
treatment (see below). Of the 41 patients, 14 had metas-
tasis at the first visit (synchronous), 15 developed metas-
tasis during follow-up (metachronous) and 12 were
metastasis-free. Metastases were localized in lung and the
primary sites were in extremity bones. Extraskeletal, peri-
osteal, and paraosteal osteosarcomas were excluded from
this study. All slides of the cases were reviewed by two
pathologists to confirm diagnosis. Patients received preo-
perative, postoperative or no chemotherapy according to
degree of tumor stage. Necrosis area was defined by
using the Huvos grading system, as described in detail
[21,22]. Accordingly, we subdivided patients into two
groups (<90%) and (≥90%) based on chemonecrosis area
as indicated by the European Cooperative Osteosarcoma
Study Group coordinated by the Istituto Ortopedico Riz-
zoli (COSS) [21,22], a partner of the present study.
Chemotherapy protocols included methotrexate (12 g/
m2) with leucovorin rescue, cisplatin (90-150 mg/m2),
doxorubicin (60-90 mg/m2), and ifosfamide (6-10 g/m2).
The scheduled duration of chemotherapy ranged from
24 to 38 weeks. For chemotherapy patients, surgery was
scheduled to take place between weeks 9 and 11 and
radiotherapy was not used. We collected clinical data
from all patients including age, sex, tumor site, necrosis
area after chemotherapy and surgical stage.
Immunohistochemistry
Biopsies before chemotherapy were fixed and paraffin
embedded. Conventional immunohistochemical studies
were performed on 5-6 μm section, as previously
described in detail [16,22]. Briefly, slides were immersed
in a water bath (W-cap Bioptica) and incubated for 30
minutes at 95°C, then cooled for 20 minutes at room
temperature. Sections were then incubated for 10 min-
utes in 3% hydrogen peroxide in distilled water, and
washed in PBS for 5 minutes. Slides were incubated
with the primary antibody (mouse-monoclonal YY1
diluted 1:100 sc7341 Santa Cruz) for 30 minutes in a
Dako Autostainer device. The signal was then visualized
with streptavidina-biotina Dako REAL Detection System
Peroxidase/DAB, Rabbit/Mouse Dako Autostainer. Slides
were counterstained with hematoxylin. Washing steps
were included after each incubation. All samples were
stained with vimentin as tissue quality controls while
positive and negative conventional controls were used to
test antibody as already reported [16]. All controls gave
satisfactory and reproducible results. Digital photos were
obtained with Olympus Vanox AHBS3. The staining of
tumor cells for evaluation of YY1 was scored from 0 to
4 (0=no staining; 1=weak 1-25% positive cells; 2= mod-
erate 26%-50% positive cells; 3= strong 51%-75% positive
cells; 4= very strong 76%-100% positive cells. This score
was checked by two independent observers blinded for
clinical outcome or other biological tumor features. Dis-
crepant cases were decided on consensus.
Statistical analysis
Data were analyzed with SPSS 13.0 software. Results are
reported as mean ± SD. YY1 was considered as a dis-
crete variable and the patients were stratified into two
classes: high score as 3-4, (>51-100% positive cells) and
low score as 0-2, (0-<50% positive cells) of YY1.
ANOVA was used to assess difference for continuous
variables (age and mean follow-up) while Pearson chi
square test was used to examine differences between
YY1 expression and each clinical variable: gender, tumor
site, histotype, chemonecrosis, presence of metastasis at
diagnosis and occurrence of metastasis at follow-up (n =
41). Survival periods were counted in months from the
date of first visit to date of death or last follow-up
before study closure. Follow-up data started at time of
diagnosis allowing a minimum of 3.8 months (mean
47.0 ± 25.3 month range, 3.8-95 months). Mean age of
the sample was 19.4 ± 15.5 with a range from 4 to 76
years. Metastasis-free period was counted in months
from the date of surgery to date of detection of first
metastasis, since no local relapses occurred. We used
life-table method to estimate the metastasis-free survival
and overall survival for low and high levels of YY1
expression. Multivariate Cox regression analysis was
used to evaluate the effect of YY1 expression on metas-
tasis occurrence and survival independently of age, gen-
der, histotype and chemonecrosis. A p value <0.05 was
considered as statistically significant.
Results
YY1 overexpression in osteosarcoma tissues
Immunohistochemistry revealed that all normal bone
tissues analyzed (n = 10) were almost negative to YY1
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antibody or in some cases normal bone showed faint
and diffuse cytoplasm staining, as previously reported
[16]. Figure 1 shows two representative examples of
osteosarcoma with the low score (2) and high score (4)
of YY1 antibody localized predominantly in nuclei
(95%). Table 1 shows YY1 scoring with respect to clini-
cal variables. Table 2 summarizes the characteristics of
the study population stratified by high and low YY1
expression (see methods). A total of 61% of tumor sam-
ples were positive to YY1 staining (nuclear staining)
with strong intensity (score 3-4, >51-100% positive cells)
while 39% showed a lower degree of YY1 staining (score
1-2, <50% of positive cells). Distal femur and tibia were
the most common sites (53.7% and 19.5% respectively).
The majority of tumors arose on extremities. There was
no difference in degree of YY1 expression in histological
subgroups (i.e. chondroblastic, fibroblastic and
osteoblastic types, p = 0.557) and age. Twenty-seven
patients were free of metastasis at baseline while 15
(55.6%) developed metastasis during follow-up. Of these,
80% were positive to YY1 (51-100% positive cells) (p =
0.004). In univariate analysis, death occurred in 64% of
YY1 strong positive patients (p = 0.005). Importantly,
multivariate Cox regression analysis revealed that a high
level of YY1 expression (score 3-4) was predictive of
poor metastasis-free survival (HR = 4.690, 95%CI =
1.079-20.396; p = 0.039) (Table 3 and Figure 2). The
estimated overall survival (after 60 months of follow-up)
calculated by life-table method (Table 4) was 34% for
patients with a high YY1 score and 79% for those with a
low YY1 score. Multivariate Cox regression analysis
indicated that YY1 expression is predictive of mortality
(HR = 8.353, 95%CI = 1.863-37.451, p = 0.006) as an
independent variable with respect to age, gender, histo-
type and chemonecrosis (Figure 3 and Table 5).
Discussion
The present study demonstrates that a high level of YY1
protein expression increases the risk of metastasis (4.69-
fold) and poor survival (8.35-fold) in osteosarcoma
patients independently of covariates such as age, gender,
histotype, and chemonecrosis. We report that the high-
est range of YY1 expression is a statistically significant
prognostic factor setting the 5-year survival rate to 34%
in patients with osteosarcoma. These results are in line
with literature data and with the tumor necrosis rate
which is currently the strongest clinical prognostic fac-
tor after chemotherapy [2,23,24].
Overall, the molecular complexity of osteosarcoma
makes the known prognostic markers of limited utility
[12,25]. A multiple panel of biomarkers in addition to
clinical parameters would be useful for predicting prog-
nosis [25]. In this setting, YY1 is the first osteosarcoma
marker whose overexpression has been correlated with
low metastasis-free and poor overall survival in a higher
frequency of cases (61% in the present study) than
reported in other studies leading us to set a higher cut-
off value (YY1 > 50%) [12]. In addition, low YY1
Figure 1 Two comparative examples of YY1 expression in
osteosarcomas. A, osteobastic osteosarcoma specimen with 2 as
score of immunoreactivity to YY1 at lower magnification (20x); B,
the same specimen as in A at higher magnification (100x); C,
osteoblastic osteosarcoma specimen with 4 as score of
immunoreactivity to YY1 (20x); D, the same osteoblastic
osteosarcoma specimen as in C at higher magnification (100x). YY1
protein was localized in nuclei of the cells.
Table 1 YY1 scoring as continuous variable
YY1 - 0 YY1 - 1 YY1 - 2 YY1 - 3 YY1 - 4
Clinical features 4 patients 9 patients 4 patients 9 patients 15 patients
Age 16.3 ± 7.4 30.1 ± 23.9 13.0 ± 2.2 12.3 ± 8.9 19.7 ± 13.4
Gender
Male 25.0 66.7 100.0 66.0 73.3
Chemonecrosis ≥ 90% 50.0 33.3 25.0 33.3 40.0
Metachronous metastasis (%)* 0 12.5 75.0 60.0 88.9
Mortality 25.0 22.2 50.0 66.7 53.3
Mean follow -up 50.3 ± 31.6 39.7 ± 21.0 62.0 ± 37.3 43.6 ± 23.0 48.5 ± 25.6
*Data reported are from the 27 patients free of metastasis at baseline and expressed in percentage
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expression was correlated with best clinical prognosis
and absence of metastasis during follow-up. One com-
mon limitation of immunohistochemical studies is both
antibody sensitivity and specificity. To address these
issues, we used an antibody previously tested by other
groups [26,27]. Immunohistochemistry was also per-
formed in two different Institutions which studied dif-
ferent subgroups of patients [26,27]. YY1 was localized
in the nucleus irrespective of histologic subtype, patient
age, or tumor site. Although this is a small study, there
was no significant difference in YY1 scores between
Table 2 Univariate analysis of YY1 expression and clinical pathological characteristics of patients
Clinical features Number of
cases 41
YY1(low) (0-50% positive cells) 16
cases (39.0%)
YY1 (strong) (51%-100% positive cells) 25
cases (61.0%)
p
Age (4-76) 19.4 ± 15.6 24.4 ± 19.1 16.2 ± 12.0 0.099
Gender
Male 68.3 62.5 72.0 0.524
Chemonecrosis ≥ 90% 36.6 37.5 36.0 0.923
Synchronous metastasis (%) 34.1 25.0 40.0 0.323
Metachronous metastasis (%) * 55.6 25.0 80.0 0.004
Mean time to metastasis (range 3-
76 months)
29.4 ± 19.2 37.6 ± 22.9 22.9 ± 13.1 0.047
Mortality 46.3 18.8 64.0 0.005
Mean follow-up (range 3-95
months)
47.0 ± 25.3 49.8 ± 27.5 45.2 ± 24.2 0.578
* Data reported are from the 27 patients free of metastasis at baseline
Table 3 Multivariate Cox regression analysis on incidence of metachronous metastasis
Variable HR Metachronous metastasis (95.0% CI) p
Age 1.005 0.969-1.043 0.772
Gender (male) 1.057 0.230-4.850 0.944
Histology 1.201 0.321-4.493 0.786
Chemonecrosis ≥ 90% 0.717 0.219-2.348 0.582
YY1 in primary site (strong vs low) 4.690 1.079-20.396 0.039
HR= Hazard Rate
Figure 2 Cox regression of cumulative metastasis-free survival
rate. The graph shows the cumulative metastasis-free survival of
high grade osteosarcoma patients using Cox multivariate analysis.
The data indicates that high score of YY1 is associated with higher
probability of developing metastasis during the follow up (HR =
4.690, 95%CI = 1.079-20.396; p = 0.039). HR= hazard ratio;
CI=confidence interval.
Figure 3 Cox regression of cumulative survival rate of all
patients. The graph shows the cumulative overall survival rate of
high grade osteosarcoma patients (n = 41) using Cox multivariate
analysis. The data indicates that higher score of YY1 (3-4) predicts
mortality during the follow up. (HR = 8.353, 95%CI = 1.863-37.451, p
= 0.006) HR= hazard ratio; CI=confidence interval.
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younger and older age groups suggesting its role in
tumor development. The design of the present study
stemmed from our previous in vitro observations
demonstrating that YY1 was overexpressed in osteosar-
coma cells and tissues with more aggressive phenotype
[16-18]. This is in agreement with YY1 overexpression
in prostate, gastrointestinal [26,27] and other tumors
[14]. Moreover, in an in vivo mice model of osteosar-
coma YY1 was also shown to play a key role in meta-
static growth [19] by regulating vascular supply [20,28].
Interestingly, the majority of patients analyzed
revealed strong YY1 expression and showed poor
response to chemotherapy based on Huvos grading sys-
tem. Although the correlation between YY1 expression
and prognosis may merely be a statistical association,
the protein dosage points to a functional relationship
between YY1 overexpression and a more aggressive
tumor phenotype. Noteworthy, literature data from
other tumoral and non-tumoral tissues provide at least
some evidence for the proposed functional relationship.
Resistance to Fas-mediated apoptosis of prostate cancer
cells is linked to YY1 [29]. A further potential link
between YY1 overexpression and chemoresistance lies
in the fact that YY1 regulates DR5 gene [30]. We have
recently demonstrated that YY1 is involved in CXCR4
and VEGF pathways [19,20] which have both been
genetically amplified and correlated with poor survival
of soft-tissue sarcomas [8,31,32]. In addition, YY1 over-
expression increases resistance to taxana treatment in
epithelial ovarian cancer [32]. Furthermore, in a meta-
analysis, YY1 was scored as the most significant gene
upregulated in metastatic breast cancer [33]. Thus, YY1
screening may be useful in optimizing individual ther-
apy management at the time of diagnosis in these
patients.
In conclusion, we demonstrated for the first time that
high YY1 expression in osteosarcoma is associated with
metastasis development and mortality independently of
age, gender, histotype and presence of metastasis at
baseline. While other studies have analyzed larger
cohorts of patients [34,35], this is the first time a prog-
nostic marker has demonstrated poor outcome by mul-
tivariate analysis. If data are confirmed in a larger
cohort of patients, YY1 may become part of a multiple
panel of biomarkers clinically useful for osteosarcoma
prognosis.
Conclusions
Our study established that overexpression of YY1 in pri-
mary site of osteosarcoma is associated with the occur-
rence of metastasization and poor clinical prognosis.
This may be a novel marker for patients with
osteosarcoma.
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